Forget Eli Lilly: 3 Biotech Stocks to Buy Instead
A few years ago, Eli Lilly (NYSE: LLY) was far from the hottest stock in the biopharmaceutical world. But times have changed. Today, Lilly ranks as the biggest healthcare company in the world. It still has tremendous growth prospects with its diabetes, obesity, and Alzheimer's disease drugs.
So is Lilly the top stock for healthcare investors right now? Nope. Forget Eli Lilly. Here are three biotech stocks to buy instead.
You might be surprised to see (NASDAQ: AMGN) on a list of better biotech stocks to buy than Eli Lilly. While Lilly's shares have soared more than 50% year to date, Amgen is up by only a high single-digit percentage. Amgen also posted a net loss in the first quarter of 2024 based on generally accepted accounting principles (GAAP).
Source Fool.com
Amgen Inc. Aktie
Starke Kaufsignale für Amgen Inc.: Keine Sell-Einschätzungen, nur Buy-Einschätzungen.
Für Amgen Inc. ergibt sich ein leicht positives Potenzial, angesichts eines Kursziels von 304 € im Vergleich zu 289.1 €.
